News | March 30, 2022
TDB approves funding for MIM in MedTech
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
Recommendation is based on pivotal data from the phase III POLARIX study
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The drug is indicated for use in combination with other drugs
He has over 25 years of rich experience in marketing and business in various sectors
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
Subscribe To Our Newsletter & Stay Updated
